Loading...
Topotecan — Export Intelligence Report
2025-Q4 · TransData Nexus
PHARMA TRADE INTELLIGENCE
INDIA EXPORT INTELLIGENCE REPORT
Topotecan
2025-Q4
Comprehensive analysis of India’s topotecan export trade — suppliers, buyers, prices, routes, and every shipment record.
45
Shipments
$292K
Trade Value
12
Suppliers
14
Buyers
15
Countries
Scan for online report
Talk to our analyst: +91 95950 78788
https://transdatanexus.com/pharmaceutical/topotecan
01
PART I — OVERVIEW
Executive Summary
At-a-glance KPIs, key findings, and strategic positioning of India’s topotecan trade — 2025-Q4
KEY TAKEAWAY
Topotecan 2025-Q4 exports total $291.8K across 15 countries, with INTAS PHARMACEUTICALS LTD commanding 61.3% market share.
TOTAL SHIPMENTS
45
2025-Q4
EXPORT VALUE
$291.8K
FOB USD
TOTAL QUANTITY
26.1K
units shipped
INDIAN SUPPLIERS
12
unique exporters
GLOBAL BUYERS
14
unique importers
DESTINATIONS
15
countries
MEDIAN UNIT PRICE
$7.74
per unit
TOP-5 SHARE
98.2%
of total USD
BRANDED SHARE
62.2%
28 shipments
DOSAGE FORMS
2
product types
6 KEY FINDINGS
1
INTAS PHARMACEUTICALS LTD is India's #1 Topotecan exporter with $178.9K (61.3% market share).→ §5, Indian Supplier Rankings
2
Topotecan reached 15 countries, with Brazil as the top destination ($88.2K).→ §4, Global Destination Map
3
Market concentration is high (HHI: 4623) — top 10 suppliers control 99.9% of exports.→ §5, Indian Supplier Rankings
4
92.9% of buyers (13 of 14) source from a single Indian supplier — potential poaching opportunities.→ §6, Global Buyer Rankings
5
Injection dominates (90.4%) across 2 dosage forms.→ §7, Price Benchmarks
6
15 countries have ≤5 Indian suppliers — easy-entry markets for SME exporters.→ §9, Strategic Opportunities
WHO THIS REPORT IS FOR
S SUPPLIERS (Indian pharma exporters)
- See which buyers your competitors are shipping to, at what price, through which ports
- Identify buyers that are single-sourced (poaching opportunities)
- Benchmark your pricing and catalog vs the Top 25
B BUYERS (global importers)
- Discover which Indian exporters supply this product and what they sell
- Benchmark the price you are paying vs the market median by country and dosage
- Identify alternative suppliers with proven exports to similar destinations
Figure 1.1 INTAS PHARMACEUTICALS LTD leads in volume — how do 12 exporters compare on price × volume?
Source: TransData Nexus Pharma Trade Intelligence · Licensed database & govt sources
How to read: Every bubble is one Indian topotecan exporter. X-axis = shipment count; Y-axis = average unit price; bubble size = total revenue. Dashed lines split at the median — exporters in the top-right (Bulk Leaders) combine high volume with premium pricing.
HOW TO READ THIS REPORT
60 seconds
Scan this page — KPIs, thesis, flagship chart, top findings
5 minutes
Read every Key Takeaway line across §1–§9
30 minutes
Read sections tagged for your role ([S] or [B]) end-to-end
In depth
Drill into §10 for your country · supplier / buyer directories at end
02
PART I — OVERVIEW
About This Report
Data sources, methodology, trust signals, and what this Topotecan report covers
KEY TAKEAWAY
Every figure in this report is grounded in real commercial topotecan trade records. Data comes from official customs filings and public trade sources, runs through a multi-layer quality process, and lands in a clean, consistent report you can rely on.
S FOR SUPPLIERS
Every competitor benchmark, market share figure, and buyer list in this report comes from verified commercial shipments — not surveys or estimates. Use them with confidence when planning your next pitch.
B FOR BUYERS
Every supplier profile, price benchmark, and trade route in this report reflects what that supplier actually ships — real volumes, real destinations, real prices. Use them to qualify and compare Indian topotecan suppliers.
§2.1 Reporting parameters · the scope of this 2025-Q4 Topotecan India trade report
Product scope
Topotecan
All variants merged — branded and generic formulations of topotecan
Time period
2025-Q4
October, November, December 2025 — a single-quarter snapshot
Data sources
Official & public trade records
Government customs filings, public trade databases and licensed commercial feeds
Geography
India origin → global
Indian sea and air ports shipping to destination markets worldwide
Currency
USD (FOB)
Declared Free-on-Board value at the Indian port of loading
Shipments analysed
45
Every commercial topotecan trade record in the period, aggregated and deduplicated
§2.2 Our quality process · Figure 2.1
Figure 2.1 From raw trade records to a clean report — the four quality pillars.
Source: TransData Nexus Pharma Trade Intelligence · Licensed database & govt sources
How to read: Raw trade data (left) flows through four quality checks — source verification, format standardisation, entity matching, and deduplication — to produce the clean, reliable data (right) behind every chart and table in this report.
§2.3 Trust signals · what you can rely on in the numbers you read
DATA COVERAGE
10M+
Pharmaceutical trade records across the full TransData Nexus platform.
COUNTRIES
150+
Origin and destination countries covered in the global pharma trade database.
DATA ACCURACY
99.9%
Validation rate on core fields — supplier, buyer, product, quantity, value.
UPDATE FREQUENCY
Daily
Platform refresh cadence. This report is a snapshot from the same live data.
§2.4 Limitations · what the data does and does not tell you
WHAT THIS DATA DOES AND DOES NOT SAY
- Prices are at the Indian port of loading (FOB), not the final delivered cost in the destination country. Freight, insurance, import duty and local margin are not included.
- This is a single-quarter snapshot. Multi-quarter trends, year-over-year growth and historical comparisons are available on the full platform.
- A small number of records have incomplete transport mode or destination port fields; these appear blank in the shipment register but are still counted in totals.
- This report is a commercial intelligence tool, not a legal audit. For high-stakes decisions, cross-reference with the underlying trade records via the full platform.
03
PART II — MARKET STRUCTURE
Quarterly Trade Overview
Monthly trends, regional performance, and ranking shifts — 2025-Q4
KEY TAKEAWAY
2025-Q4 followed a v-curve: Oct $107.0K, Nov $87.9K, Dec $96.9K. Shipment counts rose across the quarter.
S FOR SUPPLIERS
Track which months your competitors were most active, which destinations rose or fell, and whether the Nov dip hit your segment. The bump charts show rank movement — watch for rivals climbing past you.
B FOR BUYERS
Identify whether your current Indian supplier maintained steady shipments through the quarter, or whether they pulled back. Steady suppliers during dips signal reliable partnerships.
1
$107.0K
Oct USD
9 shipments
2
$87.9K
Nov USD
-17.8% MoM
3
$96.9K
Dec USD
+10.1% MoM
4
V-curve
Q4 growth shape
Oct → Nov → Dec
Fig 3.1 Nov dipped 17.8% in USD but shipment count kept climbing.
Source: TransData Nexus Pharma Trade Intelligence · Licensed database & govt sources
How to read: Blue bars = monthly USD. Orange line = shipment count. When bars drop but line rises, average shipment value fell. Insight: Oct opened at $107K, making it the strongest month by value.
Fig 3.2 Q4 cumulative USD reached $292K.
Source: TransData Nexus Pharma Trade Intelligence · Licensed database & govt sources
How to read: The curve shows the running total across the quarter. A steeper slope means that month contributed more revenue. Insight: The curve’s steepest section reveals which month drove the most trade value.
Fig 3.3 $19K dip in Nov, $9K recovery in Dec.
Source: TransData Nexus Pharma Trade Intelligence · Licensed database & govt sources
How to read: Blue bars = absolute monthly value. Red = month-over-month loss; green = gain. Insight: Nov’s dip was fully recovered by Dec.
Fig 3.4 Regional breakdown by month — which corridors swung most?
Source: TransData Nexus Pharma Trade Intelligence · Licensed database & govt sources
How to read: Each coloured layer is one destination region. Layer height = USD in that month. Insight: The top region contributed the most, while the smallest region had the least volume.
§3.1 Monthly summary
| Oct | $107K | 9 shipments |
| Nov | $88K | 9 shipments |
| Dec | $97K | 27 shipments |
| Q4 Total | $292K | 45 shipments |
Source: TransData Nexus Pharma Trade Intelligence · Licensed database & govt sources
Fig 3.5 Top 10 destination countries by monthly USD rank — who’s rising?
Source: TransData Nexus Pharma Trade Intelligence · Licensed database & govt sources
How to read: Each line traces a country’s monthly rank. Lines crossing = rank swaps. Insight: Netherlands held #1 throughout the quarter.
Fig 3.6 Top 10 Indian exporters by monthly USD rank.
Source: TransData Nexus Pharma Trade Intelligence · Licensed database & govt sources
How to read: Each line traces a supplier’s monthly rank. Flat = stable position; crossing = rank change. Insight: INTAS PHARMACEUTICALS LTD maintained its leading position.
04
PART II — MARKET STRUCTURE
Global Destination Map
Which countries import topotecan from India, how much they buy, and who supplies each market
KEY TAKEAWAY
Brazil absorbs 30.2% of India’s 2025-Q4 topotecan trade ($88.2K). Beyond the top 10 destinations, 15 countries have fewer than 5 Indian suppliers each — white-space markets where new entrants face minimal competition. Europe has 5 destination countries, the widest regional diversity.
S FOR SUPPLIERS
Use the flow map and lanes table to see which destinations your competitors dominate. For small and mid-size suppliers: look beyond the leading markets — the 15 countries in the long tail have fewer than 5 Indian suppliers each and low competitive barriers.
B FOR BUYERS
Find your country on the map to see how much topotecan India ships to your market, who the top suppliers are, and whether you’re in a concentrated or competitive corridor.
Asia
$22K
7.5% of trade
4 countries · 9 shipments
Europe
$66K
22.8% of trade
5 countries · 22 shipments
Americas
$115K
39.6% of trade
2 countries · 5 shipments
Africa
$88K
30.2% of trade
4 countries · 9 shipments
Fig 4.1 Brazil is the #1 corridor ($88K) — 15 flow arcs from India radiate across 4 continents.
Source: TransData Nexus Pharma Trade Intelligence · Licensed database & govt sources
How to read: The world map shows every country colored by how much Indian topotecan it receives (light = low, dark = high). Orange arcs radiate from India to the top 15 destinations; arc thickness = USD value. All destinations are labeled with country name + USD.
§4.1 Top 10 bilateral trade lanes (India → destination) with top Indian suppliers
| # | Destination | Total USD | Ships | #1 Indian supplier | USD | #2 Indian supplier | USD | #3 Indian supplier | USD |
|---|---|---|---|---|---|---|---|---|---|
| 1 | Brazil | $88K | 3 | INTAS PHARMACEUTICALS LTD | $85K | NIVIRA EXPORTS | $3K | — | — |
| 2 | Morocco | $84K | 3 | SUN PHARMACEUTICAL INDUSTRIES LTD | $84K | — | — | — | — |
| 3 | Netherlands | $58K | 6 | INTAS PHARMACEUTICALS LTD | $58K | — | — | — | — |
| 4 | United States | $27K | 2 | INTAS PHARMACEUTICALS LTD | $27K | — | — | — | — |
| 5 | Afghanistan | $19K | 1 | VENUS REMEDIES LTD | $19K | — | — | — | — |
| 6 | Greece | $6K | 5 | INTAS PHARMACEUTICALS LTD | $6K | — | — | — | — |
| 7 | Kenya | $3K | 3 | R.S. SURGIPHARM PVT LTD | $1K | UNITED BIOTECH PVT LTD | $1K | EFFORTS PHARMA | $296 |
| 8 | Hungary | $2K | 7 | INTAS PHARMACEUTICALS LTD | $2K | — | — | — | — |
| 9 | Nepal | $2K | 2 | UNITED BIOTECH PVT LTD | $2K | — | — | — | — |
| 10 | Rwanda | $2K | 2 | COSMOS HEALTHCARE | $2K | — | — | — | — |
Table 4.1 — Top 10 destination countries ranked by trade value, with the largest Indian suppliers for each market.
Fig 4.2 Asia leads at 7.5% of USD — but Brazil is the single largest market.
Region → country treemap
Source: TransData Nexus Pharma Trade Intelligence · Licensed database & govt sources
How to read: Column width = region USD share. Within each column, cells are stacked by country, height = share within region.
§4.2 Destination concentration
30.2%
#1 country share
Brazil alone
94.4%
Top 5 share
5 of 15 countries
100.0%
Top 15 share
Long tail of 0 countries = -0.0%
HHI 2264
Destination HHI
Moderately concentrated
15
Countries served
Global pharma reach from India
5
Europe countries
Widest regional diversity
Source: TransData Nexus trade data platform
05
PART III — WHO’S IN THIS MARKET
Indian Supplier Rankings & Profiles
12 Indian exporters ranked by value — profiles, portfolios, and competitive intelligence
KEY TAKEAWAY
INTAS PHARMACEUTICALS LTD ($178.9K, 61.3% share) and SUN PHARMACEUTICAL INDUSTRIES LTD ($83.7K) together control 90.0% of India’s 2025-Q4 topotecan trade. The top 5 suppliers hold 98.2%. 12 companies shipped at least once.
S FOR SUPPLIERS
Find your rank, your competitors’ ranks, and the gap in USD/share between you. The profile pages show each top supplier’s buyer portfolio, dosage mix and route map — your competitive-intelligence toolkit.
B FOR BUYERS
Find potential Indian topotecan suppliers ranked by size, catalog breadth and destination reach. The profile pages reveal which suppliers have proven trade lanes to your region.
Fig 5.1 INTAS PHARMACEUTICALS LTD leads by $95K over SUN PHARMACEUTICAL INDUSTRIES LTD — top 12 Indian exporters ranked by trade value
Source: TransData Nexus Pharma Trade Intelligence · Licensed database & govt sources
How to read: Each bar = one Indian supplier ranked by USD. The (#N) shows their rank by shipment count — mismatches reveal pricing strategy. Insight: HUMANKIND PHARMA is #10 by value but #2 by volume.
Fig 5.2 INTAS PHARMACEUTICALS LTD also leads by shipment count (25) but ranking shifts for volume-heavy players
Source: TransData Nexus Pharma Trade Intelligence · Licensed database & govt sources
How to read: Same suppliers re-ranked by shipment count. The (#N) shows their rank by USD value. Insight: HUMANKIND PHARMA moves from #2 by volume to #10 by value — fewer but higher-value shipments.
05
PART III — WHO’S IN THIS MARKET
Supply Landscape — Archetypes & Concentration
How India’s 12 topotecan suppliers split into strategic segments
KEY TAKEAWAY
3 suppliers (25%) generate 96.3% of total trade value. The market splits into four archetypes: Market Leaders, High-Value specialists, Volume players, and a long tail.
Fig 5.3 INTAS PHARMACEUTICALS LTD and SUN PHARMACEUTICAL INDUSTRIES LTD sit in the leaders zone — high volume AND high value.
Source: TransData Nexus Pharma Trade Intelligence · Licensed database & govt sources
How to read: Each bubble is one Indian supplier. X-axis = shipment count (log scale); Y-axis = total USD value (log scale); bubble size = revenue. Blue dashed lines split at the median. Market Leaders (top-right) combine high volume with high value. Premium Niche (top-left) ship fewer but higher-value consignments. Volume Players (bottom-right) compete on quantity. Long-Tail (bottom-left) are small or occasional exporters. Conclusion: the log scale reveals clear strategic clusters — use this map to identify where your company sits relative to competitors.
Fig 5.4 25% of suppliers = 96.3% of USD — classic concentration.
Source: TransData Nexus Pharma Trade Intelligence · Licensed database & govt sources
How to read: Top bar = supplier %, bottom bar = USD %. The gap = market concentration.
Product variety — how many formulations each supplier ships
| # | Supplier | Dosage forms | Countries | USD |
|---|---|---|---|---|
| 1 | INTAS PHARMACEUTICALS LTD | 2 | 7 | $179K |
| 2 | SUN PHARMACEUTICAL INDUSTRIES LTD | 1 | 1 | $84K |
| 3 | VENUS REMEDIES LTD | 1 | 1 | $19K |
| 4 | NIVIRA EXPORTS | 1 | 1 | $3K |
| 5 | UNITED BIOTECH PVT LTD | 1 | 2 | $3K |
| 6 | COSMOS HEALTHCARE | 1 | 1 | $2K |
| 7 | R.S. SURGIPHARM PVT LTD | 1 | 1 | $1K |
| 8 | OCEAN PHARMACEUTICAL | 1 | 1 | $786 |
| 9 | BAKER & DAVIS PVT LTD | 1 | 1 | $551 |
| 10 | HUMANKIND PHARMA | 1 | 1 | $504 |
Table 5.1 — The more dosage forms a supplier ships, the more versatile their manufacturing capability.
05
PART III — WHO’S IN THIS MARKET
Supply Landscape — India Origin Geography & Concentration
Which Indian cities and states are the topotecan manufacturing hubs
KEY TAKEAWAY
Ahmedabad and Mumbai together account for $270K of India’s 2025-Q4 topotecan trade.
Fig 5.5 Ahmedabad (4 exporters, $182K) and Mumbai (4 exporters, $88K) are India’s topotecan capitals.
Source: TransData Nexus Pharma Trade Intelligence · Licensed database & govt sources
How to read: Orange bubbles mark major pharma hub cities; bubble size = USD value. Every hub labeled.
§5.1 Supplier concentration metrics
98.2%
Top 5 share
5 of 12 suppliers
99.9%
Top 10 share
10 of 12 suppliers
96.3%
Top 25% share
3 suppliers = 96% USD
HHI 4623
Supplier HHI
Concentrated
12
Total suppliers
shipped Topotecan in 2025-Q4
5+ cities
Indian hubs
Ahmedabad and Mumbai lead
§5.2 Coming next: 1 exporter deep-dive profiles
Each of the top 1 suppliers gets a dedicated 2-page profile with:
- 6 KPI cards — trade value, shipments, countries, buyers, avg ship value, branded share
- Dosage form breakdown — what formulations they ship
- Monthly trend — Oct / Nov / Dec trajectory
- Trade flow map — supplier → country → importer connections
- Buyer portfolio with lock-in analysis
SUPPLIER PROFILES IN THIS REPORT
| #1 | INTAS PHARMACEUTICALS LTD | $179K |
#1
EXPORTER PROFILE #1 OF 1
INTAS PHARMACEUTICALS LTD
Ahmedabad · India’s #1 topotecan supplier by USD · 2025-Q4
2025-Q4 USD
$179K
61.3% market share
SHIPMENTS
25
avg $7K/ship
COUNTRIES
7
destination markets
BUYERS
5
4 single-sourced
BRANDED
48%
of shipments
DOSAGE FORMS
2
product types
TOP 7 DESTINATIONS
Brazil is the #1 market at $85K (48% of trade), followed by Netherlands at $58K. 7 countries served.
| # | Country | USD | Ships | Share |
|---|---|---|---|---|
| 1 | Brazil | $85K | 1 | 47.7% |
| 2 | Netherlands | $58K | 6 | 32.4% |
| 3 | United States | $27K | 2 | 15.2% |
| 4 | Greece | $6K | 5 | 3.3% |
| 5 | Hungary | $2K | 7 | 1.2% |
| 6 | Austria | $263 | 2 | 0.1% |
| 7 | Poland | $133 | 2 | 0.1% |
MONTHLY TREND
Oct peaked at $107K. Nov was the weakest at $0.
PRODUCT MIX
Injection dominates at 85% of trade. Solution (15.2%) and others are secondary formulations.
TOP BUYERS · 4/4 LOCKED IN
4 of 4 buyers source exclusively from this supplier — high lock-in with low competitive threat.
| Buyer | Country | USD | Status |
|---|---|---|---|
| Undisclosed buyer | Hungary | $104K | N/A |
| BROCACEF NL:EU HUB | Netherlands | $56K | ⚠ Locked |
| EVERSANA LIFE SCIENCES… | United States | $13K | ⚠ Locked |
| ACCORD HEALTHCARE SING… | Greece | $6K | ⚠ Locked |
| BROCACEF NL : EU HUB | Netherlands | $102 | ⚠ Locked |
#1
EXPORTER PROFILE #1 OF 1 — TRADE FLOW MAP
INTAS PHARMACEUTICALS LTD — Supplier → Country → Importer
5 destination countries, top 5 importers per country
Fig 5.P1.3 Brazil absorbs $85K — the thickest ribbon.
Source: TransData Nexus Pharma Trade Intelligence · Licensed database & govt sources
How to read: Left = Indian supplier. Middle = destination countries (ordered by USD). Right = importers within each country. Ribbon thickness = USD value; color = country. Every node labeled with name + USD + ships. Showing top 5 destinations and up to 3 importers per destination.
06
PART III — WHO’S IN THIS MARKET
Global Buyer Rankings & Intelligence
14 importers across 15 countries — who is buying Indian topotecan and how much
KEY TAKEAWAY
The demand side is dramatically more fragmented than supply: the top 12 importers together hold only 63.3% of total USD. 93% of buyers source from a single Indian supplier — a vast pool of lock-in candidates.
S FOR SUPPLIERS
Find the importers buying from your competitors. The rankings reveal who has volume, who pays well, and who sources from multiple Indian suppliers (potential pitch targets).
B FOR BUYERS
See where you rank among global importers of Indian topotecan. Compare your USD and shipment count against peers in your country and dosage segment.
Fig 6.1 SUN PHARMACEUTICALS MOROCCO LL is the #1 importer at $84K (28.7%) — top 12 by trade value
Source: TransData Nexus Pharma Trade Intelligence · Licensed database & govt sources
How to read: Each bar = one global importer ranked by USD.
Fig 6.2 Re-ranked by shipment count — compare with Fig 6.1 for divergences
Source: TransData Nexus Pharma Trade Intelligence · Licensed database & govt sources
How to read: Same 12 importers re-ranked by shipment count.
§6.1 Sourcing diversity — how many Indian suppliers does each buyer use?
93%
Single-source
13 buyers rely on exactly 1 Indian supplier
0%
Dual-source
0 buyers use 2 Indian suppliers
7%
Multi-source (3–4)
1 buyers diversified across 3–4
0%
Broad-source (5+)
0 buyers with 5+ Indian suppliers
06
PART III — WHO’S IN THIS MARKET
Single-Source Buyers & Price Benchmark
Lock-in opportunities grouped by country + where each buyer sits on the price spectrum
KEY TAKEAWAY
These importers source topotecan from exactly one Indian supplier. For each one, the table shows the incumbent, price, and dosage.
S FOR SUPPLIERS
This is your target list. Each row is a buyer locked into one competitor. Offer 5–10% better pricing to win the second-source slot.
B FOR BUYERS
If you see your company here, you are fully dependent on one Indian supplier. Consider qualifying a second source.
§6.2 Single-source lock-in by country
Netherlands 2 single-source buyers
| Importer | Current supplier | USD | Unit $ | Dosage |
|---|---|---|---|---|
| BROCACEF NL:EU HUB | INTAS PHARMACEUTICAL… | $56K | $10.279 | Injection |
| BROCACEF NL : EU HUB | INTAS PHARMACEUTICAL… | $102.290 | $0.096 | Injection |
United Arab Emirates 2 single-source buyers
| Importer | Current supplier | USD | Unit $ | Dosage |
|---|---|---|---|---|
| MEPL INTERNATIONAL LLC | OCEAN PHARMACEUTICAL | $785.786 | $39.289 | Injection |
| ZMC EXPRESS CARGO FZCO | HUMANKIND PHARMA | $503.953 | $3.150 | Injection |
Morocco 1 single-source buyers
| Importer | Current supplier | USD | Unit $ | Dosage |
|---|---|---|---|---|
| SUN PHARMACEUTICALS MO… | SUN PHARMACEUTICAL I… | $84K | $24.603 | Injection |
Afghanistan 1 single-source buyers
| Importer | Current supplier | USD | Unit $ | Dosage |
|---|---|---|---|---|
| W H O | VENUS REMEDIES LTD | $19K | $18.500 | Injection |
United States 1 single-source buyers
| Importer | Current supplier | USD | Unit $ | Dosage |
|---|---|---|---|---|
| EVERSANA LIFE SCIENCES… | INTAS PHARMACEUTICAL… | $13K | $7.782 | Solution |
§6.3 Price positioning — top 12 importers
| # | Importer | Country | USD | $/ship | Tier |
|---|---|---|---|---|---|
| 1 | SUN PHARMACEUTICALS … | Morocco | $84K | $28K | Mid |
| 2 | BROCACEF NL:EU HUB | Netherlands | $56K | $28K | Mid |
| 3 | W H O | Afghanistan | $19K | $19K | Mid |
| 4 | EVERSANA LIFE SCIENC… | United States | $13K | $13K | Budget |
| 5 | ACCORD HEALTHCARE SI… | Greece | $6K | $1K | Budget |
| 6 | HELOISA RICCI ALVES | Brazil | $3K | $1K | Budget |
| 7 | NIKHIL PHARMA PVT LTD | Nepal | $2K | $780.000 | Budget |
| 8 | SALAMA PHARMACEUTICA… | Kenya | $1K | $1K | Budget |
| 9 | MEPL INTERNATIONAL LLC | United Arab Emirates | $785.786 | $786.000 | Budget |
| 10 | RAPATI ENTERPRISES | Singapore | $551.021 | $551.000 | Budget |
| 11 | ZMC EXPRESS CARGO FZCO | United Arab Emirates | $503.953 | $126.000 | Budget |
| 12 | BROCACEF NL : EU HUB | Netherlands | $102.290 | $51.000 | Budget |
06
PART III — WHO’S IN THIS MARKET
Market Relationship Map
The top 12 × 12 supplier ↔ buyer network as a circular flow diagram
Fig 6.3 INTAS PHARMACEUTICALS LTD → SUN PHARMACEUTICALS MOROCCO LL is the strongest relationship.
Source: TransData Nexus Pharma Trade Intelligence · Licensed database & govt sources
How to read: Left semicircle = top 12 Indian suppliers; right = top 12 global buyers. Arc length = total USD; colored ribbons = individual relationships, thickness = USD value. Insight: follow the thickest ribbons to identify the dominant trading pairs.
07
PART IV — MARKET BEHAVIOR
Price Benchmarks & Analysis
How Indian topotecan prices vary by supplier, country and dosage form
KEY TAKEAWAY
Topotecan prices span 681× ($0.095 → $64.67). The coefficient of variation is 1.13. Dosage form, not destination, is the primary price driver.
S FOR SUPPLIERS
Use the box plot to see where your product sits on the price spectrum. The tornado chart shows exactly where you sit relative to the market median.
B FOR BUYERS
Use this section to benchmark the price you pay against the market. The percentile strip tells you if your current supplier is charging you premium, mid-market or budget rates.
§7.1 Price distribution · Table 7.1
| Statistic | Value | Interpretation |
|---|---|---|
| Min | $0.095 | Lowest observed unit price |
| P5 | $0.096 | 5th percentile |
| P25 | $3.12 | 25th percentile (Q1) |
| Median | $7.74 | 50th percentile (Q2) |
| P75 | $24.61 | 75th percentile (Q3) |
| P95 | $38.57 | 95th percentile |
| Max | $64.67 | Highest observed unit price |
| Mean | $13.76 | Arithmetic average |
| CV | 113% | Coefficient of variation (std/mean) |
Source: TransData Nexus Pharma Trade Intelligence · Licensed database & govt sources
Fig 7.1 COSMOS HEALTHCARE prices at $63.85/unit vs market median $7.74.
Source: TransData Nexus Pharma Trade Intelligence · Licensed database & govt sources
How to read: Each bar shows one supplier’s average unit price relative to the market median (dashed line). Red = above median (premium), green = below (budget).
COMMODITY KINGS
high volume · low unit price
Bulk API/tablet. Largest absolute USD despite lowest per-unit prices. e.g. INTAS PHARMACEUTICALS LTD Sourcing: best for cost-driven procurement.
BULK LEADERS
high volume · premium price
Branded-generic leaders, above-median pricing. e.g. UNITED BIOTECH PVT Sourcing: hardest to displace; compete on relationship.
LONG-TAIL
low volume · low unit price
Spot/opportunistic players. e.g. VENUS REMEDIES LTD Sourcing: first to approach for new tenders.
PREMIUM NICHE
low volume · premium price
Sterile injectables and infusions. Hospital-grade. e.g. R.S. SURGIPHARM PVT Sourcing: expect 10× price vs tablet.
07
PART IV — MARKET BEHAVIOR
Price Benchmarks & Analysis
Outlier forensics and the procurement cheat sheet — what to expect to pay by country × dosage
KEY TAKEAWAY
Extreme prices are real: the highest are specialty/sterile formulations; the lowest are bulk API. The cheat sheet matrix is the take-home reference for procurement teams.
§7.2 Outlier forensics — top 10 highest and 10 lowest unit prices
↑ TOP 10 HIGHEST USD/UNIT
| Date | Exporter | Country | Dosage | Qty | USD | $/unit | Why |
|---|---|---|---|---|---|---|---|
| Dec 2025 | COSMOS HEALTHCARE | Rwanda | Injection | 12 | $776.08 | $64.67 | Sterile formulation premium |
| Dec 2025 | COSMOS HEALTHCARE | Rwanda | Injection | 12 | $756.37 | $63.03 | Sterile formulation premium |
| Dec 2025 | OCEAN PHARMACEUT… | United Arab Emirates | Injection | 20 | $785.79 | $39.29 | Sterile formulation premium |
| Dec 2025 | UNITED BIOTECH P… | Kenya | Injection | 30 | $1K | $35.70 | Sterile formulation premium |
| Dec 2025 | R.S. SURGIPHARM … | Kenya | Injection | 50 | $1K | $30.00 | Sterile formulation premium |
| Nov 2025 | EFFORTS PHARMA | Kenya | Injection | 10 | $296.48 | $29.65 | Sterile formulation premium |
| Dec 2025 | BAKER & DAVIS PV… | Singapore | Injection | 20 | $551.02 | $27.55 | Sterile formulation premium |
| Dec 2025 | UNITED BIOTECH P… | Nepal | Injection | 30 | $782.23 | $26.07 | Sterile formulation premium |
| Nov 2025 | UNITED BIOTECH P… | Nepal | — | 30 | $778.56 | $25.95 | Specialty / small-batch |
| Nov 2025 | NIVIRA EXPORTS | Brazil | Injection | 60 | $1K | $24.74 | Sterile formulation premium |
↓ TOP 10 LOWEST USD/UNIT
| Date | Exporter | Country | Dosage | Qty | USD | $/unit | Why |
|---|---|---|---|---|---|---|---|
| Dec 2025 | INTAS PHARMACEUT… | Greece | Injection | 135 | $12.83 | $0.095 | Sterile formulation premium |
| Dec 2025 | INTAS PHARMACEUT… | Greece | Injection | 820 | $77.93 | $0.095 | Sterile formulation premium |
| Dec 2025 | INTAS PHARMACEUT… | Netherlands | Injection | 945 | $91.19 | $0.096 | Sterile formulation premium |
| Dec 2025 | INTAS PHARMACEUT… | Netherlands | Injection | 115 | $11.10 | $0.096 | Sterile formulation premium |
| Dec 2025 | INTAS PHARMACEUT… | Austria | Injection | 115 | $11.11 | $0.097 | Sterile formulation premium |
| Dec 2025 | INTAS PHARMACEUT… | Austria | Injection | 3K | $252.02 | $0.097 | Sterile formulation premium |
| Dec 2025 | INTAS PHARMACEUT… | Poland | Injection | 115 | $48.90 | $0.425 | Sterile formulation premium |
| Dec 2025 | INTAS PHARMACEUT… | Poland | Injection | 197 | $83.77 | $0.425 | Sterile formulation premium |
| Oct 2025 | YOGI CARE PHARMA… | DR Congo | Injection | 2 | $0.862 | $0.431 | Sterile formulation premium |
| Dec 2025 | INTAS PHARMACEUT… | Greece | Injection | 25 | $22.97 | $0.919 | Sterile formulation premium |
§7.3 Procurement cheat sheet — median USD/unit by country × dosage
Fig 7.2 Median unit price by country × dosage form — darker cells = higher prices.
Source: TransData Nexus Pharma Trade Intelligence · Licensed database & govt sources
How to read: Each cell shows the median price per unit for that country-dosage combination. Dark blue = expensive, light = cheap. Blank cells = no shipments in that combination.
NEGOTIATION RANGE
Use each cell value as the anchor price. Typical dynamics:
- Budget buyer: anchor − 10–15% (floor = cost + freight)
- Mid-market: anchor ± 5–10%
- Premium/tender: anchor + 10–25% (regulated, quality premium)
- Injection/infusion: always 4–10× the tablet price
KEY TAKEAWAYS
- Dosage form is the #1 price driver, not destination
- Light cells = easy-entry markets for small suppliers
- Dark cells = premium markets requiring regulatory investment
08
PART IV — MARKET BEHAVIOR
Shipping Ports & Trade Routes
Which Indian ports ship topotecan, which global ports receive it, and which corridors are high-value vs bulk
KEY TAKEAWAY
Topotecan leaves India through 5+ ports. The top 5 (AHMEDABAD AIR, INDORE AIR, DELHI AIR) handle 100.0% of total USD. AIR moves 82% of shipments.
S FOR SUPPLIERS
Use the dumbbell to classify your port as high-value hub or bulk workhorse. Note the short-sea routes — Bangladesh, Sri Lanka, Myanmar and East Africa are the easiest logistics corridors for first-time exporters.
B FOR BUYERS
Use the destination port ranking to find which Indian ports serve your market. The lead-time estimates tell you what transit time to expect.
Fig 8.1 AHMEDABAD AIR handles $179K — top 5 Indian origin ports by trade value.
Source: TransData Nexus Pharma Trade Intelligence · Licensed database & govt sources
How to read: Each bar = one Indian port. Bar length = USD value. The largest ports handle the majority of trade.
Fig 8.2 GUARULHOS is the #1 global destination port — top 21 by USD value.
Source: TransData Nexus Pharma Trade Intelligence · Licensed database & govt sources
How to read: Each bar = one destination port worldwide. Bar length = USD value received from India.
§8.1 Reference transit times for key India → global corridors
| Route | Mode | Transit time | Notes |
|---|---|---|---|
| NHAVA SHEVA SEA (JNPT) → US East Coast | Sea | 22–28 days | Via Suez; 2–3 transshipments typical |
| NHAVA SHEVA SEA (JNPT) → Lagos (Nigeria) | Sea | 18–24 days | Direct liner service available |
| MUMBAI AIR (SAHAR) → New York JFK | Air | 3–5 days | Direct cargo; cold-chain available |
| MUNDRA SEA → Rotterdam | Sea | 20–26 days | Via Suez; Hamburg also served |
| HYDERABAD AIR → London Heathrow | Air | 2–4 days | Pharma-grade cargo corridor |
| CHENNAI SEA → Chittagong (Bangladesh) | Sea | 7–12 days | Short-sea route; high frequency |
| RAXAUL → Birgunj (Nepal) | Road | 1–2 days | Land border crossing |
| NHAVA SHEVA SEA (JNPT) → Mombasa (Kenya) | Sea | 14–20 days | Direct or via Colombo hub |
Table 8.1 — Reference times based on standard shipping corridors. Air = 2–5 days; sea = 7–28 days; road = 1–2 days. Add 3–7 days for customs clearance at destination.
08
PART IV — MARKET BEHAVIOR
Shipping Ports & Trade Routes
Trade corridors — origin port to mode of transport to destination region
KEY TAKEAWAY
AIR dominates at 82% of shipments. The alluvial traces every dollar from Indian origin port through transport mode to destination region.
AIR
$289K
99.1% of USD · 82.2% of ships
SEA
$2K
0.9% of USD · 17.8% of ships
Fig 8.3 The dominant corridor is AHMEDABAD AIR → Air → LatAm ($85K).
Source: TransData Nexus Pharma Trade Intelligence · Licensed database & govt sources
How to read: Left = Indian origin ports. Middle = transport mode. Right = destination region. Ribbon thickness = USD value; color = mode. Follow the thickest ribbons to find the highest-value corridors.
09
PART V — ACTION
Strategic Opportunities & Action Plan
Market concentration, supply-chain risk, and the dependency patterns that signal where to act
KEY TAKEAWAY
Hungary is the most concentrated destination (HHI 10000, 1 suppliers). Kenya is the most competitive (HHI 4238).
S FOR SUPPLIERS
The HHI barbell shows where competitors have locked up a market (concentrated = poaching opportunity) vs where you must compete on quality (fragmented). The slope chart reveals who is gaining ground.
B FOR BUYERS
The HHI barbell tells you whether your country has enough supplier options. If concentrated (red zone), you have fewer alternatives.
Fig 9.1 Hungary (HHI 10,000) is the most concentrated — Kenya (HHI 4,238) is the most competitive.
Source: TransData Nexus Pharma Trade Intelligence · Licensed database & govt sources
What is HHI? The Herfindahl-Hirschman Index measures how concentrated a market is among its suppliers. It ranges from 0 to 10,000. Below 1,500 (green zone) = many suppliers compete openly — healthy, competitive market with low risk. 1,500–2,500 (yellow zone) = a few suppliers hold significant share — moderate concentration. Above 2,500 (red zone) = one or two suppliers dominate the market — high risk for buyers who may lose supply, and hard to break into for new suppliers. Conclusion: 15 of 15 destination markets are concentrated (red zone). 0 are competitive (green zone). Buyers in red-zone markets should urgently qualify a second Indian supplier to reduce dependency risk.
§9.1 Single-source dependencies
| Buyer | Country | Sole supplier | USD | Ships | Risk |
|---|---|---|---|---|---|
| SUN PHARMACEUTICALS … | Morocco | SUN PHARMACEUTIC… | $84K | 3 | MEDIUM |
| BROCACEF NL:EU HUB | Netherlands | INTAS PHARMACEUT… | $56K | 2 | MEDIUM |
| W H O | Afghanistan | VENUS REMEDIES LTD | $19K | 1 | MEDIUM |
| EVERSANA LIFE SCIENC… | United States | INTAS PHARMACEUT… | $13K | 1 | MEDIUM |
| ACCORD HEALTHCARE SI… | Greece | INTAS PHARMACEUT… | $6K | 5 | MEDIUM |
| HELOISA RICCI ALVES | Brazil | NIVIRA EXPORTS | $3K | 2 | MEDIUM |
| NIKHIL PHARMA PVT LTD | Nepal | UNITED BIOTECH P… | $2K | 2 | MEDIUM |
| SALAMA PHARMACEUTICA… | Kenya | UNITED BIOTECH P… | $1K | 1 | MEDIUM |
Conclusion: 12 buyers depend on exactly one Indian supplier, representing $185K in trade. For suppliers: each row is a competitor’s locked-in customer you can target.
§9.2 Multi-source resilience
| Buyer | Country | Suppliers | USD | Dominant | Resilience |
|---|
Conclusion: 0 of these buyers have HIGH resilience (3+ active suppliers). These are the hardest accounts to win but safest partners for long-term contracts.
09
PART V — ACTION
Strategic Opportunities & Action Plan
Market entry playbook and risk landscape by destination country
KEY TAKEAWAY
15 target markets with specific entry approaches. Large suppliers: focus on regulated Tier 1 markets. Small/mid-size: start with Tier 2–3 (low barrier, growing demand).
§9.3 Sourcing recommendations · Table 9.1
| Country | Tier | Lead | Price | Risk | Entry approach |
|---|---|---|---|---|---|
| Brazil | Tier 3 (emerging) | 3–5 days (air) | $1–$10/unit | LOW | First-mover advantage |
| Morocco | Tier 3 (emerging) | 3–5 days (air) | $1–$10/unit | LOW | First-mover advantage |
| Netherlands | Tier 3 (emerging) | 3–5 days (air) | $1–$10/unit | LOW | First-mover advantage |
| United States | Tier 3 (emerging) | 3–5 days (air) | $1–$10/unit | LOW | First-mover advantage |
| Afghanistan | Tier 3 (emerging) | 3–5 days (air) | $1–$10/unit | LOW | First-mover advantage |
| Greece | Tier 3 (emerging) | 3–5 days (air) | $1–$10/unit | LOW | First-mover advantage |
| Kenya | Tier 3 (emerging) | 3–5 days (air) | $1–$10/unit | LOW | First-mover advantage |
| Hungary | Tier 3 (emerging) | 3–5 days (air) | $1–$10/unit | LOW | First-mover advantage |
| Nepal | Tier 3 (emerging) | 3–5 days (air) | $1–$10/unit | LOW | First-mover advantage |
| Rwanda | Tier 3 (emerging) | 3–5 days (air) | $1–$10/unit | LOW | First-mover advantage |
| United Arab Emirates | Tier 3 (emerging) | 3–5 days (air) | $1–$10/unit | LOW | First-mover advantage |
| Singapore | Tier 3 (emerging) | 3–5 days (air) | $1–$10/unit | LOW | First-mover advantage |
| Austria | Tier 3 (emerging) | 14–28 days (sea) | $0.01–$0.10/unit | LOW | First-mover advantage |
| Poland | Tier 3 (emerging) | 14–28 days (sea) | $0.10–$1/unit | LOW | First-mover advantage |
| DR Congo | Tier 3 (emerging) | 3–5 days (air) | $0.10–$1/unit | LOW | First-mover advantage |
For suppliers: Tier 1 markets (US, UK, France) require regulatory investment but offer premium pricing. Tier 3 markets (emerging) have low barriers — ideal for first-time exporters. For buyers: Use the price band and lead time to benchmark your current supplier’s terms.
Fig 9.2 0 markets in the Growth Opportunity zone (competitive + growing). 12 in Fragile Dependency (concentrated + shrinking).
Source: TransData Nexus Pharma Trade Intelligence · Licensed database & govt sources
How to read: Each bubble = one destination. X-axis = HHI (concentration). Y-axis = growth %. Bubble size = USD. Green zone (top-left) = Growth Opportunity — competitive markets that are growing, best for new entrants. Red zone (bottom-right) = Fragile Dependency — concentrated + shrinking, high supply-chain risk. Conclusion: Key markets are the top growth opportunities.
09
PART V — ACTION
Action Plan & Easy-Entry Markets
12 prioritised actions + 15 low-competition destination countries for small & mid-size suppliers
KEY TAKEAWAY
Quick Wins: execute this quarter. Big Bets: plan for next 6–12 months. Plus 15 countries with ≤5 Indian suppliers — the best entry points for SMEs.
S
FOR SUPPLIERS
| ID | Action | Timing | Impact |
|---|---|---|---|
| A1 | Pitch top single-source buyer in Morocco | This Q | HIGH |
| A2 | Offer alternative to top multi-source buyer | This Q | HIGH |
| A3 | Audit Hungary lock-ins (HHI 10000) | This Q | MED |
| A5 | Enter Netherlands (1 suppliers) | This Q | HIGH |
| A6 | Enter Brazil (2 suppliers) | This Q | MED |
| A8 | Build Morocco distribution | 6–12m | HIGH |
| A9 | Bundle injection/infusion catalog for premium markets | 6–12m | MED |
B
FOR BUYERS
| ID | Action | Timing | Impact |
|---|---|---|---|
| A4 | Monitor rising exporters (climbers) | This Q | MED |
| A7 | Register for Brazil tenders | 6–12m | HIGH |
| A10 | Track quarterly HHI shifts across key destinations | This Q | LOW |
| A11 | Map competitor buyer portfolios quarterly | This Q | MED |
| A12 | Qualify second source for single-source buyers | This Q | MED |
§9.4 Easy-entry markets — 15 countries with ≤5 Indian suppliers
| # | Country | Region | Suppliers | Q4 USD | Growth | Barrier | Why this is easy |
|---|---|---|---|---|---|---|---|
| 1 | Netherlands | Other | 1 | $58K | +2806.2% | LOW | Only 1 Indian suppliers — near-monopoly, easy second-source entry |
| 2 | Brazil | Other | 2 | $88K | -100% | LOW | Only 2 Indian suppliers — near-monopoly, easy second-source entry |
| 3 | Morocco | Africa | 1 | $84K | 0% | LOW | Only 1 Indian suppliers — near-monopoly, easy second-source entry |
| 4 | United States | Other | 1 | $27K | +4.6% | LOW | Only 1 Indian suppliers — near-monopoly, easy second-source entry |
| 5 | Afghanistan | Asia | 1 | $19K | 0% | LOW | Only 1 Indian suppliers — near-monopoly, easy second-source entry |
| 6 | Greece | Other | 1 | $6K | -98% | LOW | Only 1 Indian suppliers — near-monopoly, easy second-source entry |
| 7 | Hungary | Other | 1 | $2K | +104.3% | LOW | Only 1 Indian suppliers — near-monopoly, easy second-source entry |
| 8 | Kenya | Africa | 3 | $3K | 0% | LOW | Low competition (3 suppliers), accessible market |
| 9 | Nepal | Asia | 1 | $2K | 0% | LOW | Only 1 Indian suppliers — near-monopoly, easy second-source entry |
| 10 | Rwanda | Africa | 1 | $2K | 0% | LOW | Only 1 Indian suppliers — near-monopoly, easy second-source entry |
| 11 | United Arab Emirates | Other | 2 | $1K | 0% | LOW | Only 2 Indian suppliers — near-monopoly, easy second-source entry |
| 12 | Singapore | Asia | 1 | $551 | 0% | LOW | Only 1 Indian suppliers — near-monopoly, easy second-source entry |
| 13 | Austria | Other | 1 | $263 | 0% | LOW | Only 1 Indian suppliers — near-monopoly, easy second-source entry |
| 14 | Poland | Other | 1 | $133 | 0% | LOW | Only 1 Indian suppliers — near-monopoly, easy second-source entry |
| 15 | DR Congo | Africa | 1 | $1 | -100% | LOW | Only 1 Indian suppliers — near-monopoly, easy second-source entry |
This report covers 45 2025-Q4 Topotecan shipments.
TransData Nexus tracks 3.37M+ shipments across all pharmaceuticals since 2020.
→ transdatanexus.com/pharmaceutical/topotecan
10
PART VI — EVIDENCE REGISTER
Comprehensive Shipment Records by Region
Authoritative source behind all analytics in this report — every shipment appears exactly once
KEY TAKEAWAY
This section contains every one of the 45 2025-Q4 topotecan shipments, organised by Region → Exporter → Shipment rows. No row is duplicated.
S FOR SUPPLIERS
Jump to any destination country to see exactly who your competitors ship to, what they charge, through which port, and how often.
B FOR BUYERS
Jump to your country to see every Indian topotecan shipment that arrived in 2025-Q4: supplier, price, dosage, port.
§10.1 Global totals
SHIPMENTS
45
across all regions
TOTAL USD
$292K
2025-Q4 FOB value
UNITS
26.1K
tablets, capsules, etc.
SUPPLIERS
12
Indian exporters
BUYERS
14
global importers
COUNTRIES
15
destinations
§10.2 Regional breakdown
§10.3 Key insights from the data
Africa is the largest region at $88K (30.2%), spanning 4 countries.
12 Indian suppliers shipped to 14 buyers across 15 countries — average shipment value $6K.
Top 0 markets: .
Every row below is real customs data — date, importer, dosage, brand, quantity, unit price, total USD, origin port, destination port, and transport mode.
§10.4 How to read a country page
1
6 KPI cards — shipments, USD, qty, exporters, importers, avg unit price.
2
4 mini-lists — top exporters, importers, dosages, monthly trend.
3
Shipment register — every row grouped by exporter. No row is duplicated or omitted.
10
PART VI — DRILL-DOWN · AFRICA
Region: Africa
4 countries · 9 shipments · $88K · 6 Indian suppliers · 4 buyers
SHIPMENTS
9
USD
$88K
COUNTRIES
4
SUPPLIERS
6
BUYERS
4
HHI
9,033
concentrated
Top 4 destination countries in Africa
1
Morocco (95.0%)
$84K
2
Kenya (3.3%)
$3K
3
Rwanda (1.7%)
$2K
4
DR Congo (0.0%)
$0.862
Top 6 Indian suppliers into Africa
1
SUN PHARMACEUTICAL INDUSTRIES LTD
$84K
2
COSMOS HEALTHCARE
$2K
3
R.S. SURGIPHARM PVT LTD
$1K
4
UNITED BIOTECH PVT LTD
$1K
5
EFFORTS PHARMA
$296.48
6
YOGI CARE PHARMACEUTICAL PVT LTD
$0.862
Top 2 Africa importers
1
SUN PHARMACEUTICALS MOROCCO LL · Morocco
$84K
2
SALAMA PHARMACEUTICALS LTD · Kenya
$1K
Top 1 dosage forms
1
Injection
$88K
Monthly trend
| Month | Ships | USD | Avg/ship |
|---|---|---|---|
| Oct | 1 | $0.862 | $0.862 |
| Nov | 4 | $84K | $21K |
| Dec | 4 | $4K | $1K |
Shipment register · 9 rows · grouped by exporter
| # | Date | Importer | Country | Dosage | Qty | Unit | Unit $ | Total $ | Origin | Dest | Mode |
|---|---|---|---|---|---|---|---|---|---|---|---|
| SUPPLIER #1 — SUN PHARMACEUTICAL INDUSTRIES LTD · 3 shipments · $84K | |||||||||||
| 1 | Nov 2025 | SUN PHARMACEUTICALS MOROCCO LL | Morocco | Injection | 1.0K | VLS | $24.61 | $25K | INDORE AIR | CASABLANCA | AIR |
| 2 | Nov 2025 | SUN PHARMACEUTICALS MOROCCO LL | Morocco | Injection | 2.0K | VLS | $24.60 | $49K | INDORE AIR | CASABLANCA | AIR |
| 3 | Nov 2025 | SUN PHARMACEUTICALS MOROCCO LL | Morocco | Injection | 400 | VLS | $24.60 | $10K | INDORE AIR | CASABLANCA | AIR |
| SUPPLIER #2 — COSMOS HEALTHCARE · 2 shipments · $2K | |||||||||||
| 4 | Dec 2025 | UNLISTED BUYER | Rwanda | Injection | 12 | NOS | $64.67 | $776.08 | AHMEDABAD AIR | KIGALI - | AIR |
| 5 | Dec 2025 | UNLISTED BUYER | Rwanda | Injection | 12 | NOS | $63.03 | $756.37 | AHMEDABAD AIR | KIGALI - | AIR |
| SUPPLIER #3 — R.S. SURGIPHARM PVT LTD · 1 shipments · $1K | |||||||||||
| 6 | Dec 2025 | UNKNOWN BUYER | Kenya | Injection | 50 | VLS | $30.00 | $1K | MUMBAI AIR (SAHAR) | NAIROBI | AIR |
| SUPPLIER #4 — UNITED BIOTECH PVT LTD · 1 shipments · $1K | |||||||||||
| 7 | Dec 2025 | SALAMA PHARMACEUTICALS LTD | Kenya | Injection | 30 | NOS | $35.70 | $1K | DELHI AIR | NAIROBI | AIR |
| SUPPLIER #5 — EFFORTS PHARMA · 1 shipments · $296.48 | |||||||||||
| 8 | Nov 2025 | UNLISTED BUYER | Kenya | Injection | 10 | NOS | $29.65 | $296.48 | MUMBAI AIR (SAHAR) | NAIROBI | AIR |
| SUPPLIER #6 — YOGI CARE PHARMACEUTICAL PVT LTD · 1 shipments · $0.862 | |||||||||||
| 9 | Oct 2025 | UNLISTED BUYER | DR Congo | Injection | 2 | NOS | $0.431 | $0.862 | AHMEDABAD AIR | LUMBUMBASHI | AIR |
10
PART VI — DRILL-DOWN · ASIA
Region: Asia
4 countries · 9 shipments · $22K · 5 Indian suppliers · 5 buyers
SHIPMENTS
9
USD
$22K
COUNTRIES
4
SUPPLIERS
5
BUYERS
5
HHI
7,210
concentrated
Top 4 destination countries in Asia
1
Afghanistan (84.5%)
$19K
2
Nepal (7.1%)
$2K
3
United Arab Emirates (5.9%)
$1K
4
Singapore (2.5%)
$551.02
Top 5 Indian suppliers into Asia
1
VENUS REMEDIES LTD
$19K
2
UNITED BIOTECH PVT LTD
$2K
3
OCEAN PHARMACEUTICAL
$785.79
4
BAKER & DAVIS PVT LTD
$551.02
5
HUMANKIND PHARMA
$503.95
Top 5 Asia importers
1
W H O · Afghanistan
$19K
2
NIKHIL PHARMA PVT LTD · Nepal
$2K
3
MEPL INTERNATIONAL LLC · United Arab Emirates
$785.79
4
RAPATI ENTERPRISES · Singapore
$551.02
5
ZMC EXPRESS CARGO FZCO · United Arab Emirates
$503.95
Top 2 dosage forms
1
Injection
$21K
2
Unknown
$778.56
Monthly trend
| Month | Ships | USD | Avg/ship |
|---|---|---|---|
| Oct | 0 | $0.0000 | — |
| Nov | 3 | $1K | $342.61 |
| Dec | 6 | $21K | $3K |
Shipment register · 9 rows · grouped by exporter
| # | Date | Importer | Country | Dosage | Qty | Unit | Unit $ | Total $ | Origin | Dest | Mode |
|---|---|---|---|---|---|---|---|---|---|---|---|
| SUPPLIER #1 — VENUS REMEDIES LTD · 1 shipments · $19K | |||||||||||
| 1 | Dec 2025 | W H O | Afghanistan | Injection | 1.0K | VLS | $18.50 | $19K | DELHI AIR | KABUL | AIR |
| SUPPLIER #2 — UNITED BIOTECH PVT LTD · 2 shipments · $2K | |||||||||||
| 2 | Nov 2025 | NIKHIL PHARMA PVT LTD | Nepal | 30 | PCS | $25.95 | $778.56 | DELHI AIR | KATHMANDU - TRIBHUVA | AIR | |
| 3 | Dec 2025 | NIKHIL PHARMA PVT LTD | Nepal | Injection | 30 | NOS | $26.07 | $782.23 | DELHI AIR | KATHMANDU - TRIBHUVA | AIR |
| SUPPLIER #3 — OCEAN PHARMACEUTICAL · 1 shipments · $785.79 | |||||||||||
| 4 | Dec 2025 | MEPL INTERNATIONAL LLC | United Arab Emirates | Injection | 20 | NOS | $39.29 | $785.79 | AHMEDABAD AIR | DUBAI | AIR |
| SUPPLIER #4 — BAKER & DAVIS PVT LTD · 1 shipments · $551.02 | |||||||||||
| 5 | Dec 2025 | RAPATI ENTERPRISES | Singapore | Injection | 20 | NOS | $27.55 | $551.02 | MUMBAI AIR (SAHAR) | SINGAPORE | AIR |
| SUPPLIER #5 — HUMANKIND PHARMA · 4 shipments · $503.95 | |||||||||||
| 6 | Nov 2025 | ZMC EXPRESS CARGO FZCO | United Arab Emirates | Injection | 40 | NOS | $3.12 | $124.64 | MUMBAI AIR (SAHAR) | DUBAI WORLD CENTRAL | AIR |
| 7 | Nov 2025 | ZMC EXPRESS CARGO FZCO | United Arab Emirates | Injection | 40 | NOS | $3.12 | $124.64 | MUMBAI AIR (SAHAR) | DUBAI WORLD CENTRAL | AIR |
| 8 | Dec 2025 | ZMC EXPRESS CARGO FZCO | United Arab Emirates | Injection | 40 | NOS | $3.18 | $127.34 | MUMBAI AIR (SAHAR) | DUBAI WORLD CENTRAL | AIR |
| 9 | Dec 2025 | ZMC EXPRESS CARGO FZCO | United Arab Emirates | Injection | 40 | NOS | $3.18 | $127.34 | MUMBAI AIR (SAHAR) | DUBAI WORLD CENTRAL | AIR |
10
PART VI — DRILL-DOWN · EUROPE
Region: Europe
5 countries · 22 shipments · $66K · 1 Indian suppliers · 4 buyers
SHIPMENTS
22
USD
$66K
COUNTRIES
5
SUPPLIERS
1
BUYERS
4
HHI
10,000
concentrated
Top 5 destination countries in Europe
1
Netherlands (87.3%)
$58K
2
Greece (8.9%)
$6K
3
Hungary (3.2%)
$2K
4
Austria (0.4%)
$263.13
5
Poland (0.2%)
$132.67
Top 1 Indian suppliers into Europe
1
INTAS PHARMACEUTICALS LTD
$66K
Top 3 Europe importers
1
BROCACEF NL:EU HUB · Netherlands
$56K
2
ACCORD HEALTHCARE SINGLE MEMBER SA · Greece
$6K
3
BROCACEF NL : EU HUB · Netherlands
$102.29
Top 1 dosage forms
1
Injection
$66K
Monthly trend
| Month | Ships | USD | Avg/ship |
|---|---|---|---|
| Oct | 6 | $8K | $1K |
| Nov | 0 | $0.0000 | — |
| Dec | 16 | $58K | $4K |
Shipment register · 22 rows · grouped by exporter
| # | Date | Importer | Country | Dosage | Qty | Unit | Unit $ | Total $ | Origin | Dest | Mode |
|---|---|---|---|---|---|---|---|---|---|---|---|
| SUPPLIER #1 — INTAS PHARMACEUTICALS LTD · 22 shipments · $66K | |||||||||||
| 1 | Oct 2025 | ACCORD HEALTHCARE SINGLE MEMBER SA | Greece | Injection | 895 | VLS | $5.02 | $4K | AHMEDABAD AIR | ATHENS | AIR |
| 2 | Oct 2025 | ACCORD HEALTHCARE SINGLE MEMBER SA | Greece | Injection | 262 | VLS | $5.02 | $1K | AHMEDABAD AIR | ATHENS | AIR |
| 3 | Oct 2025 | UNLISTED BUYER | Hungary | Injection | 90 | VLS | $3.61 | $325.21 | AHMEDABAD AIR | BUDAPEST, | AIR |
| 4 | Oct 2025 | UNLISTED BUYER | Hungary | Injection | 90 | VLS | $4.19 | $376.77 | AHMEDABAD AIR | BUDAPEST, | AIR |
| 5 | Oct 2025 | UNLISTED BUYER | Netherlands | Injection | 263 | VLS | $5.39 | $1K | MUNDRA SEA | ROTTERDAM | SEA |
| 6 | Oct 2025 | UNLISTED BUYER | Netherlands | Injection | 95 | VLS | $5.39 | $511.78 | MUNDRA SEA | ROTTERDAM | SEA |
| 7 | Dec 2025 | ACCORD HEALTHCARE SINGLE MEMBER SA | Greece | Injection | 25 | NOS | $0.919 | $22.97 | AHMEDABAD AIR | ATHENS | AIR |
| 8 | Dec 2025 | BROCACEF NL : EU HUB | Netherlands | Injection | 945 | VLS | $0.096 | $91.19 | MUNDRA SEA | Rotterdam | SEA |
| 9 | Dec 2025 | BROCACEF NL : EU HUB | Netherlands | Injection | 115 | VLS | $0.096 | $11.10 | MUNDRA SEA | Rotterdam | AIR |
| 10 | Dec 2025 | BROCACEF NL:EU HUB | Netherlands | Injection | 5.3K | VLS | $10.28 | $55K | AHMEDABAD AIR | AMSTERDAM, SCHIPHOL | AIR |
| 11 | Dec 2025 | BROCACEF NL:EU HUB | Netherlands | Injection | 115 | VLS | $10.28 | $1K | AHMEDABAD AIR | AMSTERDAM, SCHIPHOL | AIR |
| 12 | Dec 2025 | UNLISTED BUYER | Hungary | Injection | 36 | VLS | $7.79 | $280.41 | AHMEDABAD AIR | BUDAPEST, | AIR |
| 13 | Dec 2025 | UNLISTED BUYER | Hungary | Injection | 36 | VLS | $7.68 | $276.52 | AHMEDABAD AIR | BUDAPEST, | AIR |
| 14 | Dec 2025 | UNLISTED BUYER | Hungary | Injection | 36 | VLS | $8.06 | $290.14 | AHMEDABAD AIR | BUDAPEST, | AIR |
| 15 | Dec 2025 | UNLISTED BUYER | Hungary | Injection | 40 | VLS | $7.71 | $308.29 | AHMEDABAD AIR | BUDAPEST, | AIR |
| 16 | Dec 2025 | UNLISTED BUYER | Hungary | Injection | 36 | VLS | $7.74 | $278.47 | AHMEDABAD AIR | BUDAPEST, | AIR |
| 17 | Dec 2025 | ACCORD HEALTHCARE SINGLE MEMBER SA | Greece | Injection | 820 | VLS | $0.095 | $77.93 | MUNDRA SEA | Piraeus | SEA |
| 18 | Dec 2025 | ACCORD HEALTHCARE SINGLE MEMBER SA | Greece | Injection | 135 | VLS | $0.095 | $12.83 | MUNDRA SEA | Piraeus | AIR |
| 19 | Dec 2025 | UNLISTED BUYER | Austria | Injection | 2.6K | VLS | $0.097 | $252.02 | MUNDRA SEA | Genoa | SEA |
| 20 | Dec 2025 | UNLISTED BUYER | Austria | Injection | 115 | VLS | $0.097 | $11.11 | MUNDRA SEA | Genoa | SEA |
| 21 | Dec 2025 | UNLISTED BUYER | Poland | Injection | 197 | VLS | $0.425 | $83.77 | MUNDRA SEA | Gdynia | SEA |
| 22 | Dec 2025 | UNLISTED BUYER | Poland | Injection | 115 | VLS | $0.425 | $48.90 | MUNDRA SEA | Gdynia | SEA |
10
PART VI — DRILL-DOWN · AMERICAS
Region: Americas
2 countries · 5 shipments · $115K · 2 Indian suppliers · 3 buyers
SHIPMENTS
5
USD
$115K
COUNTRIES
2
SUPPLIERS
2
BUYERS
3
HHI
9,499
concentrated
Top 2 destination countries in Americas
1
Brazil (76.4%)
$88K
2
United States (23.6%)
$27K
Top 2 Indian suppliers into Americas
1
INTAS PHARMACEUTICALS LTD
$112K
2
NIVIRA EXPORTS
$3K
Top 2 Americas importers
1
EVERSANA LIFE SCIENCES SERVICES LLC · United States
$13K
2
HELOISA RICCI ALVES · Brazil
$3K
Top 2 dosage forms
1
Injection
$88K
2
Solution
$27K
Monthly trend
| Month | Ships | USD | Avg/ship |
|---|---|---|---|
| Oct | 2 | $99K | $49K |
| Nov | 2 | $3K | $1K |
| Dec | 1 | $14K | $14K |
Shipment register · 5 rows · grouped by exporter
| # | Date | Importer | Country | Dosage | Qty | Unit | Unit $ | Total $ | Origin | Dest | Mode |
|---|---|---|---|---|---|---|---|---|---|---|---|
| SUPPLIER #1 — INTAS PHARMACEUTICALS LTD · 3 shipments · $112K | |||||||||||
| 1 | Oct 2025 | EVERSANA LIFE SCIENCES SERVICES LLC | United States | Solution | 1.7K | VLS | $7.78 | $13K | AHMEDABAD AIR | CHICAGO, IL | AIR |
| 2 | Oct 2025 | UNLISTED BUYER | Brazil | Injection | 5.4K | VLS | $15.70 | $85K | AHMEDABAD AIR | GUARULHOS | AIR |
| 3 | Dec 2025 | UNLISTED BUYER | United States | Solution | 1.6K | VLS | $8.42 | $14K | AHMEDABAD AIR | CHICAGO O'HARE INT'L | AIR |
| SUPPLIER #2 — NIVIRA EXPORTS · 2 shipments · $3K | |||||||||||
| 4 | Nov 2025 | HELOISA RICCI ALVES | Brazil | Injection | 60 | SET | $24.74 | $1K | MUMBAI AIR (SAHAR) | Guarulhos | AIR |
| 5 | Nov 2025 | HELOISA RICCI ALVES | Brazil | Injection | 60 | SET | $24.74 | $1K | MUMBAI AIR (SAHAR) | Guarulhos | AIR |
10
PART VI — EVIDENCE REGISTER
Indian Supplier Directory
All 12 Indian topotecan exporters — complete list ranked by USD
KEY TAKEAWAY
This directory lists every Indian company that shipped topotecan in 2025-Q4.
S FOR SUPPLIERS
Find yourself and your competitors. Compare shipment count, USD, and destination regions.
B FOR BUYERS
Search for potential Indian suppliers. Filter by dosage form and destination region.
| # | Supplier | City | Ships | USD | Dosage forms | Primary regions |
|---|---|---|---|---|---|---|
| 1 | INTAS PHARMACEUTICALS LTD | AHMEDABAD | 25 | $179K | Solution, Injection | Americas, Europe |
| 2 | SUN PHARMACEUTICAL INDUSTRIES LTD | MUMBAI | 3 | $84K | Injection | Africa |
| 3 | VENUS REMEDIES LTD | Behra | 1 | $19K | Injection | Asia |
| 4 | NIVIRA EXPORTS | MUMBAI | 2 | $3K | Injection | Americas |
| 5 | UNITED BIOTECH PVT LTD | NEW DELHI | 3 | $3K | Injection | Asia, Africa |
| 6 | COSMOS HEALTHCARE | AHMEDABAD | 2 | $2K | Injection | Africa |
| 7 | R.S. SURGIPHARM PVT LTD | AHMEDABAD | 1 | $1K | Injection | Africa |
| 8 | OCEAN PHARMACEUTICAL | VADODARA | 1 | $785.79 | Injection | Asia |
| 9 | BAKER & DAVIS PVT LTD | MUMBAI | 1 | $551.02 | Injection | Asia |
| 10 | HUMANKIND PHARMA | Mumbai | 4 | $503.95 | Injection | Asia |
| 11 | EFFORTS PHARMA | VADODARA | 1 | $296.48 | Injection | Africa |
| 12 | YOGI CARE PHARMACEUTICAL PVT LTD | AHMEDABAD | 1 | $0.862 | Injection | Africa |
10
PART VI — EVIDENCE REGISTER
Global Buyer Directory
All 12 global topotecan importers — complete list ranked by USD
KEY TAKEAWAY
This directory lists every company that imported Indian topotecan in 2025-Q4.
S FOR SUPPLIERS
Search for potential customers by country and dosage form.
B FOR BUYERS
Find your company and see which Indian supplier serves you.
| # | Buyer | Country | Ships | USD | Primary supplier | Dosage forms |
|---|---|---|---|---|---|---|
| 1 | SUN PHARMACEUTICALS MOROCCO LL | Morocco | 3 | $84K | SUN PHARMACEUTICAL I… | Injection |
| 2 | BROCACEF NL:EU HUB | Netherlands | 2 | $56K | INTAS PHARMACEUTICAL… | Injection |
| 3 | W H O | Afghanistan | 1 | $19K | VENUS REMEDIES LTD | Injection |
| 4 | EVERSANA LIFE SCIENCES SERVICES LLC | United States | 1 | $13K | INTAS PHARMACEUTICAL… | Solution |
| 5 | ACCORD HEALTHCARE SINGLE MEMBER SA | Greece | 5 | $6K | INTAS PHARMACEUTICAL… | Injection |
| 6 | HELOISA RICCI ALVES | Brazil | 2 | $3K | NIVIRA EXPORTS | Injection |
| 7 | NIKHIL PHARMA PVT LTD | Nepal | 2 | $2K | UNITED BIOTECH PVT LTD | Injection |
| 8 | SALAMA PHARMACEUTICALS LTD | Kenya | 1 | $1K | UNITED BIOTECH PVT LTD | Injection |
| 9 | MEPL INTERNATIONAL LLC | United Arab Emirates | 1 | $785.79 | OCEAN PHARMACEUTICAL | Injection |
| 10 | RAPATI ENTERPRISES | Singapore | 1 | $551.02 | BAKER & DAVIS PVT LTD | Injection |
| 11 | ZMC EXPRESS CARGO FZCO | United Arab Emirates | 4 | $503.95 | HUMANKIND PHARMA | Injection |
| 12 | BROCACEF NL : EU HUB | Netherlands | 2 | $102.29 | INTAS PHARMACEUTICAL… | Injection |
This report covers 45 2025-Q4 Topotecan shipments.
TransData Nexus tracks 3.37M+ shipments across all pharmaceuticals since 2020.
→ transdatanexus.com/pharmaceutical/topotecan
Talk to our trade analyst
Need a custom topotecan report or a deeper dive into any market? Our team is ready.
WhatsApp: +91 95950 78788 · transdatanexus.com
PHARMA TRADE INTELLIGENCE
Thank you for reading
This report is part of the TransData Nexus Pharma Trade Intelligence series, covering 366 pharmaceutical products exported from India.
Every figure is grounded in real commercial trade records — official customs filings and licensed databases. No surveys, no estimates, no fake data.
Need a custom report?
We can generate intelligence for any pharmaceutical product, any time period, any combination of source and destination countries.
Want deeper analysis?
Our team provides competitive intelligence, market entry strategy, and supply chain due diligence for pharma importers and exporters.
Scan for product page
WhatsApp: +91 95950 78788
Email: info@transdatanexus.com
Web: https://transdatanexus.com/pharmaceutical/topotecan
© 2026 TransData Nexus. All rights reserved. This report is provided for informational purposes only.
Data sourced from official customs filings and licensed commercial trade databases.
Reproduction without permission is prohibited.
Explore the full Topotecan product page
Live data, supplier directory, price trends, and trade route analysis